US 11,655,298 B2
Composition for treating fulminant acute pneumonia including CD69 antagonist
Akihiro Hasegawa, Yamaguchi (JP); Hidetaka Ogino, Yamaguchi (JP); and Toshinori Nakayama, Chiba (JP)
Assigned to YAMAGUCHI UNIVERSITY, Yamaguchi (JP); and NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY, Chiba (JP)
Appl. No. 16/342,992
Filed by YAMAGUCHI UNIVERSITY, Yamaguchi (JP); and NATIONAL UNIVERSITY CORPORATION CHIBA UNIVERSITY, Chiba (JP)
PCT Filed Oct. 20, 2017, PCT No. PCT/JP2017/038091
§ 371(c)(1), (2) Date Sep. 13, 2019,
PCT Pub. No. WO2018/074610, PCT Pub. Date Apr. 26, 2018.
Claims priority of application No. JP2016-207046 (JP), filed on Oct. 21, 2016.
Prior Publication US 2020/0055940 A1, Feb. 20, 2020
Int. Cl. C07K 16/28 (2006.01); A61P 11/00 (2006.01)
CPC C07K 16/2851 (2013.01) [A61P 11/00 (2018.01); C07K 2317/76 (2013.01)] 6 Claims
 
1. A method of treating fulminant acute pneumonia in a subject, comprising administering an effective amount of a CD69 antagonist to the subject, wherein the CD69 antagonist is administered to the subject after the subject has developed the fulminant acute pneumonia, the subject has not received administration of the CD69 antagonist before the development of the fulminant acute pneumonia, and the CD69 antagonist is an antibody that specifically recognizes CD69.